tbuckley/cabot-search huggingface dataset:
Human Papillomavirus–Induced Atypical Pigmented High-grade Dysplasia of the Scrotum
Authors: Alexander Kreuter, Steffi Silling, Frank Oellig, Ulrike Wieland
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
Authors: M. Schoels, R. Knevel, D. Aletaha, J. W. J. Bijlsma, F. C. Breedveld, D. T. Boumpas, G. Burmester, B. Combe, M. Cutolo, M. Dougados, P. Emery, D. van der Heijde, T. W. J. Huizinga, J. Kalden, E. C. Keystone, T. K. Kvien, E. Martin-Mola, C. Montecucco, M. de Wit, J. S. Smolen
Journal: Annals of the Rheumatic Diseases (2010)

<h3>Objectives</h3> To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment. <h3>Methods</h3> We conducted a systematic literature search including all clinical trials testing clinical, functional, or structural values of a targeted treatment approach. Our search covered Medline, Embase and Cochrane databases until December 2008 and also conference abstracts (2007, 2008). <h3>Results</h3> The primary search yielded 5881 citations; after the selection process, 76 papers underwent detailed review. Of these, only seven strategic clinical trials were extracted: four studies randomised patients to routine or targeted treatment, two compared two different randomised targets and one compared targeted treatment to a historical control group. Five trials dealt with early RA patients. All identified studies showed significantly better clinical outcomes of targeted approaches than routine approaches. Disability was reported in two studies with no difference between groups. Four studies compared radiographic outcomes, two showing significant benefit of the targeted approach. <h3>Conclusion</h3> Only few studies employed randomised controlled settings to test the value of treatment to a specific target. However, they provided unanimous evidence for benefits of targeted approaches. Nevertheless, more data on radiographic and functional outcomes and on patients with established RA are needed.
Long-term oral contraceptive use and the risk of breast cancer. The centers for Disease Control Cancer and Steroid Hormone Study
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial
Authors: C.J. Langer, E. Anderson, R. Jotte, J. Goldman, D. Haggstrom, M. Modiano, M. Socoteanu, D. Smith, C. Dahkil, K. Konduri, E. Kim, A. Sanford, K. Amiri, J. Weiss
Journal: Annals of Oncology (2017)
General Overview of the 14th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
Authors: Ricardo Sanz-Ruiz, Andreu M. Climent, Maria Eugenia Fernández-Santos, Adolfo Villa Arranz, Enrique Gutiérrez Ibañes, Maria Eugenia Vázquez-Álvarez, Francisco Fernández-Avilés
Journal: Circulation Research (2017)
The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness
Authors: Kevin C. Ma, Edward J. Schenck, Maria A. Pabon, Augustine M. K. Choi
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

The innate immune system induces inflammation through induction of multiple pathways including the TNFα/NF-κB signaling as well as the NLRP3 inflammasome cascade activation with production of inflammatory molecules. Pathogen associated molecular patterns are immunogenic costimulatory molecules that can activate the innate immune system in the presence of foreign pathogens. These molecularly distinct, foreign, particles initiate inflammatory and cell death cascades of the innate immune response through the binding of pathogen recognition receptors such as toll like receptors. The concept of danger associated molecular patterns was proposed in the 1990s based on observations that noninfectious critical illness produces similar inflammatory reactions. Endogenous danger signals are commonly intracellular molecules, such as nuclear or mitochondrial nucleic acids, that have individual biologic roles in non-inflammatory states. However, once released into the extracellular space, these molecular patterns stimula...
The Epstein-Barr Virus Regulome in Lymphoblastoid Cells
Authors: Sizun Jiang, Hufeng Zhou, Jun Liang, Catherine Gerdt, Chong Wang, Liangru Ke, Stefanie C.S. Schmidt, Yohei Narita, Yijie Ma, Shuangqi Wang, Tyler Colson, Benjamin Gewurz, Guoliang Li, Elliott Kieff, Bo Zhao
Journal: Cell Host & Microbe (2017)
Working in Australia
Authors: S. Kisely, J. Jones
Journal: BMJ (1999)

Recent publicity in the Australian press would suggest that there is a severe shortage of doctors, especially in states such as Western Australia.(1) The Australian Medical Association has highlighted how consequent overwork was leading doctors to misuse prescription drugs and alcohol. In the case of general practice the 47 doctors who trained in Western Australia in 1997 were not sufficient for the 62 vacancies that occurred in the state last year.(1) There are also shortages of radiation oncologists, dermatologists, and general surgeons across Australia. In response, the Australian Medical Workforce Advisory Committee (AMWAC) has recommended increasing the numbers of training positions for all three specialties.(2)

At first sight, this would suggest that there are tempting opportunities in Australia for doctors wishing to enjoy a sunny climate and experience the practice of medicine overseas. In this article we set out a number of pitfalls to be avoided when considering coming to Australia. In addition, we highlight how regulations have been tightened and include details on general practice not covered by our previous article.(3)

The perceived shortage of doctors is, in fact, very localised and largely restricted to areas of work where Australian doctors would not consider practising. Those coming to Australia therefore face a variety of registration and immigration rules designed to ensure that overseas doctors work in places or specialties the local doctors do not want to work in.

If you are coming to take up a permanent position make sure that you are sponsored by your prospective employer for permanent residence. People on a temporary work permit can be ejected from the country as soon …
Neutropenic fever prophylaxis during induction therapy for acute myeloid leukemia.
Authors: Nassim H. Nabbout
Journal: Journal of Clinical Oncology (2017)

e18531 Neutropenic Fever Prophylaxis During Induction Therapy for Acute Myeloid Leukemia Nassim Nabbout, MD, Salam Kadhem, MD, Rawaa Ebrahem, MD, Rossa Khalaf, MD, Baharat Malhotra, MD, K. James Kallail, PhD Background: Neutropenic fever is an oncological emergency [1] that occurs at a high rate in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Oral antibiotics have been considered standard of care for prophylaxis for these patients once they develop neutropenia [2]. To determine the efficacy of this approach, we conducted a retrospective review of newly diagnosed AML patients. Methods: All adult patients who underwent induction treatment for newly diagnosed AML at one Wichita, Kansas medical center between January 1, 2011 and December 31, 2013 were identified. The medical records were reviewed and pre-specified variables were collected. Results: Thirty-eight patients were included and their charts were reviewed. Nineteen (50%) were males. Thirty-six patients (95%) were white. The average white blood count on day 1 of treatment was 34000 cell/mm 3 and the range was 1300 - 305,000 cell/mm 3 . The average ANC was 3700 cell/mm 3 with the range of 10 - 28288 cell/mm 3 . All patients received prophylactic oral antibiotics once they became neutropenic. In all, but one patient, this regimen consisted of combination of levofloxacin, acyclovir, and fluconazole. Thirty-four patients (89%) developed neutropenic fever while they were on oral prophylactic antibiotics. Two patients (5%) developed septic shock. Four patients (11%) died during the first 21 days of induction, all due to infections, and three (8%) went to hospice. Causative organisms were identified in 11 patients (29%). All patients were switched to intravenous vancomycin and cefepime once they became febrile. Conclusions: Eighty-nine percent of patients developed neutropenic fever despite prophylaxis with oral antibiotics. These dismal results suggest that the current standard of care for neutropenic fever prophylaxis is ineffective and highlight the need for a different approach. Future studies should consider changing the regimens of antibiotics and/or the route of administration toward more aggressive prophylactic strategies.
Outcomes of patients with malignancy admitted to the intensive care units (ICU): A prospective study
Authors: H. Assi, V. Nohra, F. Sukhon, N. Moukalled, I. Bou Akl, D. Mukherji, M. Charafeddine, N. Abdul Halim, C. El Mouhayyar, Y. Medlej, P. Bou Khalil
Journal: Annals of Oncology (2017)
Role of an intronic polymorphism in the CREB1 gene, involved in melanogenesis, with the risk and the aggressiveness of cutaneous melanoma
Authors: J.K. Silva, C. Oliveira, B. Sá Carvalho, C. Torricelli, G.V.B. Gomez, W.D.L. Oliveira, J.A. Rinck-Junior, A.M. Moraes, M.M. Ortega, C.S.P. Lima, G.J. Lourenço
Journal: Annals of Oncology (2017)
Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian cancer: Variation with neoadjuvant chemotherapy and prognostic value
Authors: C. Bárcena, K. Rojas, L. Lema, L. Manso Sánchez, J. Rios, R. García-Martín, A. Maroto, J.L. Rodríguez-Peralto, E.M. Ciruelos Gil, D.C. Mendiola, L. Paz-Ares
Journal: Annals of Oncology (2017)
A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL
Authors: A. Naing, S. Leong, M.J. Pishvaian, A.R.A. Razak, A. Mahipal, J. Berlin, D. Cho, W. Senapedis, S. Shacham, M. Kauffman, J. Ellis, J. Meade, E. Baloglu
Journal: Annals of Oncology (2017)

Background: KPT-9274 is an oral, small molecule modulator of PAK4 (p21 activated kinase) and NAMPT (nicotinamide phosphoribosyltransferase). PAK4 is a major player in cell morphology and WNT/β-catenin signaling. NAMPT is the rate-limiting enzyme in NAD biosynthesis. Co-inhibition of these targets leads to synergistic anti-tumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, and ultimately apoptosis. Cells can utilize niacin to make NAD through an alternative pathway using NAPRT1. NAPRT1 is often absent in tumors making it a potential response biomarker. KPT-9274 demonstrates potent anti-tumor activity pre-clinically and in patient dogs with cancer. Methods: This dose escalation study evaluates KPT-9274 as a single agent and co-dosed with niacin. KPT-9274 is given QoDx3/week (28-day cycle) at a starting dose of 10 mg. The objectives are to evaluate safety and tolerability of KPT-9274, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), recommended phase 2 dose, early antitumor activities, pharmacokinetic (PK) and pharmacodynamic properties. Results: As of 02-Mar-17, 14 patients (pts: 9M/5F; median age 61) with advanced solid tumors were enrolled in 4 cohorts (10 – 40 mg). One DLT (G4 anemia) at 40 mg was reported. MTD is not yet reached. Drug-related adverse events (AEs) include G2-4 anemia (6 pts, 43%) and G3 fatigue (1 pt, 7%). The most common G2 AEs are arthralgia and myalgia (3 pts; 21% each) and influenza-like illness (2 pts; 14%). Stable disease (SD) was seen in 29% of the 14 pts. Preliminary PK analysis suggests plasma exposure was dose proportional on C1D1 increasing 4 to 5-fold by C1D24. On C1D24, the mean Cmax and AUC0-t observed in 20 – 30 mg cohorts were 319 – 1,573 ng/mL and 10,456 – 59,152 ng*hr/mL, respectively. Preliminary data indicate that treatment of KPT-9274 reduces NAD levels vs. baseline in circulating leukocytes and tumor biopsies. Analyses to correlate NAPRT1 status with response is ongoing (2 of 4 SD pts are NAPRT1-). Conclusions: Oral KPT-9274 is tolerated in pts with advanced solid malignancies. Anemia, arthralgias and myalgias are common AEs with one DLT (G4 anemia). PK is generally proportional and predictable. Clinical trial identification: NCT02702492 Legal entity responsible for the study: Karyopharm Therapeutics Inc Funding: Karyopharm Therapeutics Inc Disclosure: W. Senapedis, S. Shacham, J. Meade, J. Ellis, E. Baloglu: Employee and a stock holder of Karyopharm Therapeutics. M. Kauffman: Employee, stock holder and member of board of directors at Karyopharm Therapeutics. All other authors have declared no conflicts of interest.
Casos de Neisseria meningitidis en Grecia
Authors: J Kremastinou, G Tzanakaki, N Vakalis, A Velonaki
Journal: Eurosurveillance (1997)

En Grecia, la Neisseria meningitidis aparece en forma de casos esporadicos con algunos brotes locales de forma estacional. La declaracion de la enfermedad meningococica a las autoridades sanitarias locales y al Ministerio de Sanidad es obligatoria. En 1994, volvio a establecerse el Centro Nacional de Referencia de Meningococo (CNM) con el fin de crear una red entre los hospitales y las autoridades sanitarias locales, que pudiese contribuir a mejorar el sistema de declaracion.
Molecular epidemiology of multi- and extensively-drug-resistant Mycobacterium tuberculosis in Ireland, 2001–2014
Authors: E. Roycroft, R.F. O'Toole, M.M. Fitzgibbon, L. Montgomery, M. O'Meara, P. Downes, S. Jackson, J. O'Donnell, I.F. Laurenson, A.M. McLaughlin, J. Keane, T.R. Rogers
Journal: Journal of Infection (2017)
Brote de Escherichia coli O157 en Escocia, noviembre-diciembre 1996
Authors: J M Cowden
Journal: Eurosurveillance (1997)

En la tarde del viernes 22 de noviembre de 1996, el 'Lanarkshire Health Board’s Public Health Department' (Departamento de Salud Publica de la Secretaria de Sanidad de Lanarkshire) fue informado acerca de 15 casos de una posible infeccion por Escherichia coli O157 (cinco de los cuales habian sido confirmados microbiologicamente) en residentes de la ciudad de Wishaw en Escocia central. Todos los casos habian comido bocadillos de embutidos o carne procedentes de un carnicero de la zona o habian comido filete de anojo en salsa en una comida servida por la iglesia el 17 de noviembre de 1996, procedente del mismo carnicero. En ese momento, cabia la posibilidad de que la vinculacion entre los casos y la carne del carnicero en cuestion fuese mera coincidencia. De hecho, el carnicero habia sido galardonado recientemente con el premio al Mejor Carnicero Escoces del Ano. Sin embargo, debido a la gravedad de la infeccion, desde la manana del 23 de noviembre de 1996, se prohibio a dicho carnicero la venta de productos elaborados con carne precocinada.
Steroid switch: Reversal of resistance to abirateron acetate (AA) and prednisolone (P) combination in metastatic castration-resistant prostate cancer (mCRPC) patients
Authors: F. Gyergyay, B. Budai, K. Biro, Z. Küronya, K. Nagyivanyi, L. Geczi
Journal: Annals of Oncology (2017)
First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors
Authors: Y. Kuboki, N. Matsubara, H. Bando, K. Shitara, K. Yoh, T. Kojima, I. Ohno, H. Takahashi, K. Harano, S. Kondo, H. Hirai, C. Morizane, T. Doi
Journal: Annals of Oncology (2017)
Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial
Authors: B. Valerie, C. Mollevi, N. Chaput, S. Gourgou, D. Azria, J.F. Seitz, L. Bigot, B. Juzyna, I. Miran, J-P. Gérard, P. Laurent-Puig
Journal: Annals of Oncology (2017)
CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
Authors: Eunice S. Wang, Lionel Adés, Amir Tahmasb Fathi, Karl A Kreuzer, Megan Marie O'Meara, Shang-Ying Liang, Farhad Ravandi
Journal: Journal of Clinical Oncology (2017)

TPS7066 Background: AML is associated with poor survival rates in patients (pts) who are not eligible for intensive chemotherapy or allogeneic stem cell transplant (allo-SCT) due to advanced age, comorbidities, and/or disease risk factors. Non-intensive therapies, such as the hypomethylating agents (HMAs) azacitidine and decitabine, are frequently employed in this setting; however, response rates and survival remain suboptimal in this pt population. Vadastuximab talirine (33A) is a CD33-directed antibody conjugated to pyrrolobenzodiazepine (PBD) dimers. Upon binding, 33A is internalized and transported to the lysosomes where PBD is released via proteolytic cleavage of the linker, leading to DNA crosslinking and cell death. In preclinical studies, HMA priming followed by 33A exposure upregulated CD33 expression, increased DNA incorporation of the PBD dimer, and enhanced cytotoxicity. In a phase 1 study, 33A plus HMA was generally well tolerated without a significant pattern of off-target toxicity. Activity of the combination was markedly improved compared to historical data of HMA monotherapy, with a high MRD-negative remission rate and activity maintained in the highest risk subgroups (Fathi et al, ASH 2016). Methods: This phase 3, randomized, double-blind, placebo-controlled global study was designed to compare overall survival between pts treated with 33A plus HMA vs. pts treated with placebo plus HMA (NCT02785900). Secondary endpoints include composite complete remission rate (CR/CRi), event-free survival, and safety. Approximately 500 pts will be randomized in a 1:1 manner to one of the study arms. Investigators may select either HMA (azacitidine or decitabine). Eligible pts are adults with newly diagnosed, previously untreated, de novo or secondary AML, and have intermediate or adverse cytogenetic risk. Pts must not have AML associated with favorable risk karyotype or be a candidate for allo-SCT. Combination treatment may be repeated every 4 weeks until disease progression, leukemic recurrence, or unacceptable toxicity. Study enrollment began in June 2016.
Fragmentary Gene Sequences Negatively Impact Gene Tree and Species Tree Reconstruction
Authors: Erfan Sayyari, James B Whitfield, Siavash Mirarab
Journal: Molecular Biology and Evolution (2017)

Species tree reconstruction from genome-wide data is increasingly being attempted, in most cases using a two-step approach of first estimating individual gene trees and then summarizing them to obtain a species tree. The accuracy of this approach, which promises to account for gene tree discordance, depends on the quality of the inferred gene trees. At the same time, phylogenomic and phylotranscriptomic analyses typically use involved bioinformatics pipelines for data preparation. Errors and shortcomings resulting from these preprocessing steps may impact the species tree analyses at the other end of the pipeline. In this article, we first show that the presence of fragmentary data for some species in a gene alignment, as often seen on real data, can result in substantial deterioration of gene trees, and as a result, the species tree. We then investigate a simple filtering strategy where individual fragmentary sequences are removed from individual genes but the rest of the gene is retained. Both in simulations and by reanalyzing a large insect phylotranscriptomic data set, we show the effectiveness of this simple filtering strategy.
Updated results of the Breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts)
Authors: C. Fontaine, N. Cappoen, V. Renard, H. Van Den Bulk, P. Vuylsteke, P. Glorieux, L. Decoster, M. Vanhoeij, J. De Grève, A. Awada, H. Wildiers
Journal: Annals of Oncology (2017)
GW28-e0223 Investigation of the prevalence of Cognitive Impairment and its risk factors within the elderly population in Shanghai, China
Authors: Longbing Ren, Yongtao Zheng, Yijun Gu, Yusheng He, Bo Jiang, Wei Wang, Chunyan Wu, Han Yu, None MiaomiaoZhao, Jie Zhang, Lijuan Zhang, Jue Li
Journal: Journal of the American College of Cardiology (2017)